What is Multiple Myeloma? A Game-Based Learning Experience on Novel Treatment Strategies for Multiple Myeloma

Released On
February 28, 2019

Expires On
February 28, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology

Topic(s)
Multiple Myeloma

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by National Jewish Health and Catamount Medical Education.

 

Supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of hematologists, medical oncologists, advanced practice nurses, PAs, nurses, pharmacists and other healthcare professionals who are involved in the management of patients with multiple myeloma.

Program Overview

This enduring activity has an educational goal to improve the personalized management of patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss current and emerging treatments for patients with multiple myeloma
  • Adopt guidelines and other current evidence for the management of multiple myeloma
  • Discuss completed and ongoing clinical trials related to the care of patients with multiple myeloma
  • Employ patient-specific considerations in the development of personalized treatment plans
  • Apply updated criteria for patient risk stratification
  • Utilize current evidence related to response monitoring protocols

Faculty

Ravi Vij MD, MBA

Professor of Medicine
Section of Bone Marrow Transplantation and Leukemia
Washington University School of Medicine
Saint Louis, MO

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Jewish Health and Catamount Medical Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Ravi Vij MD, MBA

Dr. Ravi Vij has served on the Advisory Boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Inc., Karyopharm, Sanofi Genzyme, and Takeda Pharmaceuticals USA, Inc. He has also received grants from Bristol-Myers Squibb, Celgene Corporation and Takeda Pharmaceuticals USA, Inc.

Planners and Independent Reviewers

Susan Denner, MD, MS
Medical Writer
Catamount Medical Education

Dr. Denner has no financial interests/relationships or affiliations in relation to this activity.

Jennifer Green
Chief Learning Officer
Catamount Medical Education

Ms. Green has no financial interests/relationships or affiliations in relation to this activity.

Stephanie Corder, ND, RN, CHCP
Accreditation and Programs Manager
National Jewish Health

Ms. Corder has no financial relationships to disclose.

Mandy Comeau
Professional Education Programs Coordinator
National Jewish Health

Ms. Comeau has no financial relationships to disclose.

Dr. Laurie Carr
Associate Professor, Division of Oncology, Cancer Center
National Jewish Health

Dr. Carr discloses that she serves on the advisory board for Abbvie.

 

Instructions for Participation and Credit

In order to receive credit, participants must complete the pre-test questions preceding each section, view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test with a passing score of ≥ 75%, and evaluation form.

Certificates will be emailed to the participant.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatisbrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

National Jewish Health requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.